Drug Trial Radar · NCT07056777
Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer
Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
186
Planned (sponsor's estimate)
Start
Mar 25, 2025
Primary completion
Apr 30, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Zhejiang Doer Biologics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label phase Ib/IIa clinical study conducted in China, aimed at evaluating the safety tolerance, efficacy, pharmacokinetic (PK) characteristics, and immunogenicity of DR30206 in combination with standard treatment regimens for advanced or metastatic gastrointestinal tumors.
Conditions
- Gastrointestinal Cancer
Interventions
DR30206Drug
Subjects receive DR30206 intravenously
OxaliplatinDrug
Subjects receive Oxaliplatin intravenously
CapecitabineDrug
Subjects take Capecitabine orally
Calcium FolinateDrug
Subjects receive Calcium Folinate intravenously
5-FUDrug
Subjects receive 5-FU by Intravenous Bolus
Irinotecan (CPT-11)Drug
Subjects receive Irinotecan intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib: Incidence of dose limiting toxicities (DLTs)Time frame: 21 days or 28 days following first dose according to the arms.
- Phase Ib: Incidence and severity of treatment-emergent adverse events (TEAEs)Time frame: From the first dose up to 90 days after the last dose or initiation of new anti-tumor treatment
- Phase Ib: Maximum tolerated dose(MTD)Time frame: 21 days or 28 days following first dose according to the arms.
- Phase Ib: Recommended phase 2 dose (RP2D)Time frame: 21 days or 28 days following first dose according to the arms.
- Phase IIa: Objective response rate (ORR) (RECIST v1.1) of DR30206 in combination with standard therapy for the treatment of other gastrointestinal tumorsTime frame: the period from the date of initial medication to the objective recording of disease progression according to RECIST 1.1 standards or to the start of new anti-tumor treatment (whichever occurs first)
- Phase IIa: Objective response rate (ORR) (RECIST v1.1) of DR30206 in combination with standard therapy for the treatment of advanced or metastatic colorectal cancer.Time frame: the period from the date of initial medication to the objective recording of disease progression according to RECIST 1.1 standards or to the start of new anti-tumor treatment (whichever occurs first), assessed up to 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.